Coronavirus: Moderna’s vaccine enters phase 2 trial
Image Credit: shortpedia
Moderna Inc. said it has dosed the first participants in each age cohort in phase 2 clinical trial of its coronavirus vaccine candidate mRNA-1273. The Cambridge-headquartered biotech company explained in a release that the phase 2 study will evaluate the safety, reactogenicity and immunogenicity of two doses of its vaccine against the SARS-CoV-2 virus given 28 days apart. 600 health adults will be a part of the trial.